To ascertain whether the combination of danusertib or volasertib and AZD1775 could be an useful therapeutic strategy for BC CML patients, we assessed the effects of Aurora kinase A, PLK1 and WEE1 inhibition on the clonogenic potential of CD34+/BCR::ABL1+ cells isolated from 4 multi-TKI-resistant BC CML patients. This evidence concerns the gene WEE1 and chronic myelogenous leukemia, BCR-ABL1 positive.